GSK raised its 2025 sales and earnings forecasts due to strong growth in specialty HIV and cancer medicines. Despite a decline in U.S. shingles vaccine sales, GSK's shares rose. The company is preparing for leadership changes and navigating challenges in the U.S. vaccine market.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing